Stem Cell names David Allan as executive chairman

Stem Cell Therapeutics (TSX-V:SSS) has appointed David Allan as executive chairman, effective immediately, to be “responsible for the company’s operations.” He will also be elected to the board. Mr. Allan has been chairman of YM BioSciences (AMEX:YMI; TSX:YM) since its incorporation in 1994 and served as its CEO from 1998 to November, 2010. “Stem Cell [...]

YM names Glover as CEO

YM BioSciences (AMEX:YMI;TSX:YM) has appointed Dr. Nick Glover, currently president and COO, to the added post of CEO, effective with the annual meeting Nov. 18, succeeding David Allan, who will continue as chairman. “Given the rapid progress being made with our recently acquired CYT387 JAK inhibitor program, the ongoing advancement of nimotuzumab globally, and the [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

YM finishes CYT387 dosing; expands study

YM BioSciences (AMEX:YMI; TSX:YM) has concluded dose escalation in the Phase 1 portion of its Phase 1/2 clinical trial of CYT387 at the Mayo Clinic in patients with myelofibrosis, where a patient’s bone marrow is replaced by scar tissue and treatment options are limited or unsatisfactory because of efficacy and safety concerns. Twenty-one patients were treated in [...]

YM reshuffles the Cytopia deck

YM BioSciences (AMEX:YMI; TSX:YM) got more than it bargained for with its recent acquisition of Australia’s Cytopia. “When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA),” CEO David Allan told biotuesdays.com in an exclusive interview.  VDAs, which can disrupt the blood flow that feed tumours, became [...]

YM financing to help accelerate CYT387 study

YM BioSciences (AMEX:YMI; TSX:YM) has raised about $3.2-million (U.S.) through a non-brokered private placement of 2.5 million common shares at a price of $1.27 each, with proceeds earmarked for an earlier-than-planned Phase 2 component of its trial at the Mayo Clinic with CYT387 in myelofibrosis. “The recent decision by the company to accelerate the current [...]

YM begins Phase 2 brain metastases trial for nimotuzumab

YM BioSciences (AMEX:YMI; TSX:YM) enrolled its first U.S. patient at the Florida Cancer Institute in a Phase 2 clinical trial evaluating its nimotuzumab drug in patients with brain metastases from NSCLC . Last year, the U.S. Department of the Treasury’s Office of Foreign Assets Control lifted the limitation on the development of nimotuzumab in the [...]